181 related articles for article (PubMed ID: 30826660)
1. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S
Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.
Mima K; Nishihara R; Yang J; Dou R; Masugi Y; Shi Y; da Silva A; Cao Y; Song M; Nowak J; Gu M; Li W; Morikawa T; Zhang X; Wu K; Baba H; Giovannucci EL; Meyerhardt JA; Chan AT; Fuchs CS; Qian ZR; Ogino S
Clin Cancer Res; 2016 Aug; 22(15):3841-8. PubMed ID: 26957558
[TBL] [Abstract][Full Text] [Related]
3. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
Nishihara R; Lochhead P; Kuchiba A; Jung S; Yamauchi M; Liao X; Imamura Y; Qian ZR; Morikawa T; Wang M; Spiegelman D; Cho E; Giovannucci E; Fuchs CS; Chan AT; Ogino S
JAMA; 2013 Jun; 309(24):2563-71. PubMed ID: 23800934
[TBL] [Abstract][Full Text] [Related]
4. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
5. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
[TBL] [Abstract][Full Text] [Related]
6. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.
Yamauchi M; Lochhead P; Imamura Y; Kuchiba A; Liao X; Qian ZR; Nishihara R; Morikawa T; Shima K; Wu K; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT; Ogino S
Cancer Epidemiol Biomarkers Prev; 2013 Jun; 22(6):1142-52. PubMed ID: 23629521
[TBL] [Abstract][Full Text] [Related]
7. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour.
Hamada T; Liu L; Nowak JA; Mima K; Cao Y; Ng K; Twombly TS; Song M; Jung S; Dou R; Masugi Y; Kosumi K; Shi Y; da Silva A; Gu M; Li W; Keum N; Wu K; Nosho K; Inamura K; Meyerhardt JA; Nevo D; Wang M; Giannakis M; Chan AT; Giovannucci EL; Fuchs CS; Nishihara R; Zhang X; Ogino S
Eur J Cancer; 2018 Nov; 103():98-107. PubMed ID: 30219720
[TBL] [Abstract][Full Text] [Related]
9. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
[TBL] [Abstract][Full Text] [Related]
10. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
11. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
Haruki K; Kosumi K; Li P; Arima K; Väyrynen JP; Lau MC; Twombly TS; Hamada T; Glickman JN; Fujiyoshi K; Chen Y; Du C; Guo C; Väyrynen SA; Dias Costa A; Song M; Chan AT; Meyerhardt JA; Nishihara R; Fuchs CS; Liu L; Zhang X; Wu K; Giannakis M; Nowak JA; Ogino S
Br J Cancer; 2020 Apr; 122(9):1367-1377. PubMed ID: 32157241
[TBL] [Abstract][Full Text] [Related]
12. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
[TBL] [Abstract][Full Text] [Related]
13. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
Hamada T; Cao Y; Qian ZR; Masugi Y; Nowak JA; Yang J; Song M; Mima K; Kosumi K; Liu L; Shi Y; da Silva A; Gu M; Li W; Keum N; Zhang X; Wu K; Meyerhardt JA; Giovannucci EL; Giannakis M; Rodig SJ; Freeman GJ; Nevo D; Wang M; Chan AT; Fuchs CS; Nishihara R; Ogino S
J Clin Oncol; 2017 Jun; 35(16):1836-1844. PubMed ID: 28406723
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
16. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
[TBL] [Abstract][Full Text] [Related]
17. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
18. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
Kim SA; Inamura K; Yamauchi M; Nishihara R; Mima K; Sukawa Y; Li T; Yasunari M; Morikawa T; Fitzgerald KC; Fuchs CS; Wu K; Chan AT; Zhang X; Ogino S; Qian ZR
Br J Cancer; 2016 Jan; 114(2):199-206. PubMed ID: 26742007
[TBL] [Abstract][Full Text] [Related]
19. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
Jun SY; Kim M; Jin Gu M; Kyung Bae Y; Chang HK; Sun Jung E; Jang KT; Kim J; Yu E; Woon Eom D; Hong SM
Mod Pathol; 2016 Apr; 29(4):402-15. PubMed ID: 26892442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
